Raymond James Trust’s TherapeuticsMD TXMD Stock Holding History

Raymond James Trust’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-240	Closed	-$19K	–	1068
2020 Q3	$19K	Hold	240	–	–	﹤0.01%	975
2020 Q2	$15K	Hold	240	–	–	﹤0.01%	929
2020 Q1	$13K	Sell	240 -160	-40%	-$15.9K	﹤0.01%	819
2019 Q4	$48K	Hold	400	–	–	﹤0.01%	957
2019 Q3	$73K	Buy	400 +175	+78%	+$24.7K	﹤0.01%	921
2019 Q2	$29K	Hold	225	–	–	﹤0.01%	908
2019 Q1	$55K	Sell	225 -76	-25%	-$20.1K	﹤0.01%	870
2018 Q4	$58K	Sell	301 -40	-12%	-$9.76K	﹤0.01%	812
2018 Q3	$112K	Buy	341 +141	+71%	+$43.2K	0.01%	865
2018 Q2	$62K	Hold	200	–	–	﹤0.01%	855
2018 Q1	$49K	Hold	200	–	–	﹤0.01%	722
2017 Q4	$60K	Hold	200	–	–	﹤0.01%	739
2017 Q3	$53K	Hold	200	–	–	﹤0.01%	727
2017 Q2	$53K	Hold	200	–	–	﹤0.01%	718
2017 Q1	$72K	Buy	+200	New	+$61.9K	0.01%	696

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James Trust's TXMD Position: Q4 2020 in Review

Raymond James Trust sold out of TherapeuticsMD (TXMD) in Q4 2020, closing a stake of 240 shares — an estimated $19K sold.

Raymond James Trust first reported a position in TXMD in Q1 2017 and held it in 15 quarters. The position peaked at $112K in Q3 2018. 159 funds tracked by Wall St. Rank hold TXMD as of Q4 2020.

Raymond James Trust reported no remaining TherapeuticsMD position as of Q4 2020 after selling out during the quarter.
Raymond James Trust sold 240 TherapeuticsMD shares in Q4 2020, an estimated $19K.
Raymond James Trust first reported a position in TherapeuticsMD in Q1 2017 and held it in 15 quarters.
Raymond James Trust's TherapeuticsMD position peaked at $112K in Q3 2018.
159 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2020.

Based on Raymond James Trust's 13F filing for Q4 2020, filed 13 Jan 2021.